Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (322)	10/4/2000 11:12:04 AM
From: BulbaMan	Respond to of 1833

Reading the excerpt below from Biacore's Second-Half 2000 Report, I can't help but feel Axiom (and Cadus' Axiom stake) could be worth really big bucks. "Broadening the Portfolio – The Axiom Deal A key element of Biacore's strategy in the drug discovery market is to become a high value added technology supplier based around its unique SPR platform. In May, the company took a major step to achieving this goal when it acquired exclusive global rights to market a new cell based pharmacology system, HT-PS 100 from Axiom Biotechnologies Inc. As part of this deal Biacore made a USD 4 million equity investment in Axiom in order to provide the funds necessary to complete the development of this state of the art cell based system. The new HT-PS 100 system will complement Biacore's own molecular based high performance systems that are currently under development. In combination these two systems will allow Biacore to offer pharmaceutical/biotechnology companies an integrated solution of both cellular and molecular based assays that is designed to accelerate significantly the identification of quality lead compounds. Both of these new systems are expected to reach the market in the latter half of 2001. The agreement also includes co-promotion rights to selected cell lines developed by Axiom and an option for Biacore to license Axiom's multi channel high throughput system, HT-PS Ultra. Mr. Lars–Göran Andrén, Executive Chairman of Biacore, will become a Non-Executive Director of Axiom. Biacore has also been granted an option to increase its stake in the company further at a pre-determined price."